Delphine Marie

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier et al. · Oncotarget · 2018 · 136 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours

Christophe Massard, Philippe A. Cassier, Johanna C. Bendell et al. · Annals of Oncology · 2019 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).

Norbert Vey, Anthony Gonçalvès, Lionel Karlin et al. · Journal of Clinical Oncology · 2015 · 16 citations

Pharmacy, Immunology, Pharmacology +17

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Dimitrios Colevas, Krzysztof Misiukiewicz, Alexander T. Pearson et al. · Annals of Oncology · 2021 · 12 citations · Full text

Medicine, Oncology, Cancer Pharmacology +11